{"id":"all-trans-retinoic-acid","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Retinoid acid syndrome (RAS) / differentiation syndrome"},{"rate":"25-60","effect":"Headache"},{"rate":"30-50","effect":"Fever"},{"rate":"50-75","effect":"Dry skin and mucous membranes"},{"rate":"10-20","effect":"Bone pain"},{"rate":"30-50","effect":"Elevated triglycerides"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"1-5","effect":"Pseudotumor cerebri"}]},"_chembl":{"chemblId":"CHEMBL1235644","moleculeType":"Small molecule","molecularWeight":"300.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA is a vitamin A derivative that activates retinoic acid receptors (RARs), particularly RAR-alpha, which are abnormally fused to the PML gene in acute promyelocytic leukemia (APL). By binding these receptors, ATRA triggers degradation of the PML-RARA fusion protein, restoring normal differentiation pathways and causing leukemic cells to mature and undergo programmed cell death rather than proliferate.","oneSentence":"All-trans-retinoic acid (ATRA) binds to retinoic acid receptors to promote differentiation of acute promyelocytic leukemia cells and induce apoptosis of leukemic blasts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:21.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL), particularly t(15;17) positive disease"}]},"trialDetails":[{"nctId":"NCT05345002","phase":"PHASE2","title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","status":"RECRUITING","sponsor":"Stephen Bagley, MD, MSCE","startDate":"2022-11-16","conditions":"Glioma, IDH Mutation, Astrocytoma","enrollment":55},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT04919369","phase":"PHASE1","title":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dwight Owen","startDate":"2021-10-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":18},{"nctId":"NCT06484920","phase":"PHASE2","title":"A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL","status":"RECRUITING","sponsor":"Rita Assi","startDate":"2024-11-18","conditions":"Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT07355855","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01","conditions":"Rhabdomyosarcoma","enrollment":106},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT07296445","phase":"PHASE3","title":"A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)","status":"NOT_YET_RECRUITING","sponsor":"SDK Therapeutics, Inc.","startDate":"2026-01","conditions":"Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA","enrollment":120},{"nctId":"NCT04113863","phase":"PHASE2","title":"Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2019-06-18","conditions":"Breast Neoplasm Female","enrollment":76},{"nctId":"NCT01409161","phase":"PHASE2","title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Acute Promyelocytic Leukemia With PML-RARA","enrollment":151},{"nctId":"NCT07278908","phase":"PHASE2, PHASE3","title":"Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12","conditions":"ITP - Immune Thrombocytopenia","enrollment":248},{"nctId":"NCT06439888","phase":"PHASE1, PHASE2","title":"Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-07-11","conditions":"Oligometastatic Disease, Solid Tumor, Adult","enrollment":58},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT02712905","phase":"PHASE1, PHASE2","title":"An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-05","conditions":"Solid Tumors and Hematologic Malignancy","enrollment":116},{"nctId":"NCT04303169","phase":"PHASE1, PHASE2","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":146},{"nctId":"NCT06528769","phase":"PHASE2","title":"Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma","status":"RECRUITING","sponsor":"Gabriel Tinoco","startDate":"2025-09-10","conditions":"Leiomyosarcoma, Sarcoma","enrollment":16},{"nctId":"NCT07187505","phase":"NA","title":"Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-07-01","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":28},{"nctId":"NCT05438875","phase":"PHASE3","title":"The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2022-10-12","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":96},{"nctId":"NCT04305054","phase":"PHASE1, PHASE2","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Melanoma","enrollment":315},{"nctId":"NCT04305041","phase":"PHASE1, PHASE2","title":"Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":100},{"nctId":"NCT06371274","phase":"NA","title":"A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-10","conditions":"Triple-negative Breast Cancer","enrollment":29},{"nctId":"NCT07079696","phase":"PHASE2","title":"Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Dup15q Syndrome, Autism Spectrum Disorder, Therapy","enrollment":90},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT06982274","phase":"PHASE2","title":"Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-10-20","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":115},{"nctId":"NCT03031249","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-02-08","conditions":"AML","enrollment":80},{"nctId":"NCT05999812","phase":"PHASE2","title":"Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-12-19","conditions":"Colorectal Cancer","enrollment":22},{"nctId":"NCT06536413","phase":"PHASE1, PHASE2","title":"ATRA and Carfilzomib in Plasma Cell Myeloma Patients","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-29","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT04700176","phase":"PHASE2","title":"A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2022-05-02","conditions":"Multiple Myeloma","enrollment":1},{"nctId":"NCT06728631","phase":"PHASE2","title":"Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2020-06-30","conditions":"Oral Cavity Cancer, Premalignant Lesion","enrollment":22},{"nctId":"NCT06158412","phase":"PHASE2","title":"All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":25},{"nctId":"NCT02279095","phase":"PHASE2","title":"An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)","status":"COMPLETED","sponsor":"Clementia Pharmaceuticals Inc.","startDate":"2014-10-09","conditions":"Fibrodysplasia Ossificans Progressiva","enrollment":58},{"nctId":"NCT05881265","phase":"PHASE2","title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-15","conditions":"APL","enrollment":30},{"nctId":"NCT06636981","phase":"PHASE2","title":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-04","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":129},{"nctId":"NCT04282668","phase":"PHASE1","title":"A Study of TAS1440 With ATRA in Subjects With r/r AML","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-03-15","conditions":"Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT06646666","phase":"PHASE2","title":"ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":35},{"nctId":"NCT03200847","phase":"PHASE1, PHASE2","title":"Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-10-31","conditions":"Stage IV Melanoma, Stage III Melanoma, Advanced Melanoma","enrollment":26},{"nctId":"NCT00555399","phase":"PHASE1, PHASE2","title":"Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-28","conditions":"Glioblastoma Multiforme, Anaplastic Glioma","enrollment":55},{"nctId":"NCT05482451","phase":"EARLY_PHASE1","title":"Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"China Medical University Hospital","startDate":"2021-03-01","conditions":"Effect of Drug","enrollment":10},{"nctId":"NCT00382200","phase":"PHASE1, PHASE2","title":"Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-07","conditions":"Myelodysplastic Syndromes","enrollment":54},{"nctId":"NCT05832320","phase":"NA","title":"Optimum Induction Therapy of Low-risk APL","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Acute Promyelocytic Leukemia, Induction Therapy, Oral","enrollment":74},{"nctId":"NCT02942758","phase":"PHASE2","title":"Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML","status":"TERMINATED","sponsor":"University Hospital Regensburg","startDate":"2017-04-10","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03572387","phase":"PHASE2","title":"A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-08-20","conditions":"Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer","enrollment":14},{"nctId":"NCT02169609","phase":"PHASE2","title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2014-11-26","conditions":"Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy","enrollment":24},{"nctId":"NCT04793919","phase":"PHASE2","title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2019-10-09","conditions":"Acute Promyelocytic Leukemia","enrollment":89},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04897490","phase":"","title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","status":"RECRUITING","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-03-01","conditions":"Promyelocytic Leukemia, Adult Acute","enrollment":50},{"nctId":"NCT02403778","phase":"PHASE2","title":"Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-12-17","conditions":"Melanoma","enrollment":10},{"nctId":"NCT02842827","phase":"PHASE1, PHASE2","title":"A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)","status":"COMPLETED","sponsor":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","startDate":"2016-10-06","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":45},{"nctId":"NCT02751255","phase":"PHASE1, PHASE2","title":"Daratumumab in Combination With ATRA","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2016-07-06","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT00893399","phase":"PHASE3","title":"Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2010-05-12","conditions":"Acute Myeloid Leukemia","enrollment":600},{"nctId":"NCT05508191","phase":"NA","title":"Microneedle Versus Fractional CO₂ Laser for Skin Aging Treatment With Stem Cell Secretome in Indonesian Adult Women","status":"COMPLETED","sponsor":"Shannaz Nadia Yusharyahya","startDate":"2022-08-17","conditions":"Skin Aging, Transepidermal Water Loss","enrollment":30},{"nctId":"NCT03999684","phase":"PHASE2","title":"A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-05","conditions":"Adenoid Cystic Carcinoma","enrollment":18},{"nctId":"NCT05497310","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2022-07-01","conditions":"Promyelocytic Leukemia","enrollment":15},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT03624270","phase":"PHASE2","title":"Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-08-15","conditions":"Acute Promyelocytic Leukemia","enrollment":60},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT05297123","phase":"PHASE1","title":"Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2019-02-03","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03465280","phase":"","title":"Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)","status":"UNKNOWN","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2018-04-01","conditions":"Recurrent Respiratory Papillomatosis, Human Papilloma Virus","enrollment":400},{"nctId":"NCT03751917","phase":"","title":"Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-04-14","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT05175508","phase":"PHASE2, PHASE3","title":"Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-05-01","conditions":"AML, MDS, Old Age; Debility","enrollment":180},{"nctId":"NCT01404949","phase":"PHASE2","title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-07","conditions":"Acute Promyelocytic Leukemia","enrollment":17},{"nctId":"NCT05002530","phase":"PHASE4","title":"Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-11","conditions":"Post COVID-19 Anosmia (Loss of Smell)","enrollment":10000},{"nctId":"NCT05077813","phase":"PHASE2","title":"Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-12","conditions":"Tuberculosis","enrollment":250},{"nctId":"NCT04217148","phase":"PHASE2","title":"The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2020-01-01","conditions":"Immune Thrombocytopenia","enrollment":132},{"nctId":"NCT02899169","phase":"PHASE3","title":"Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-09-01","conditions":"Acute Promyelocytic Leukemia","enrollment":110},{"nctId":"NCT05016349","phase":"PHASE3","title":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.","status":"UNKNOWN","sponsor":"Mahmoud Ramadan mohamed Elkazzaz","startDate":"2021-08","conditions":"Breast Cancer Female","enrollment":160},{"nctId":"NCT03359174","phase":"PHASE2","title":"An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-05-29","conditions":"Cholangitis, Sclerosing","enrollment":2},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT04730895","phase":"PHASE1, PHASE2","title":"Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-07","conditions":"Covid19 Vaccine","enrollment":360},{"nctId":"NCT04433169","phase":"PHASE2","title":"All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck","status":"UNKNOWN","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2020-06-03","conditions":"Adenoid Cystic Carcinoma of the Head and Neck","enrollment":30},{"nctId":"NCT03304288","phase":"PHASE2","title":"The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2017-10-11","conditions":"Immune Thrombocytopenia","enrollment":168},{"nctId":"NCT04618328","phase":"PHASE2","title":"A Study of ATRA in the Treatment of ITP","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2020-11","conditions":"Immune Thrombocytopenia","enrollment":80},{"nctId":"NCT04396067","phase":"PHASE2","title":"Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2020-10","conditions":"COVID-19","enrollment":360},{"nctId":"NCT04568096","phase":"PHASE2","title":"Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2020-11","conditions":"the Lung Complication of COVID-19","enrollment":160},{"nctId":"NCT01064570","phase":"PHASE2","title":"AIDA 2000 Guidelines","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2000-05","conditions":"Acute Promyelocytic Leukemia","enrollment":600},{"nctId":"NCT01064557","phase":"NA","title":"\"AIDA\" Protocol (LAP 0493)","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"1993-10","conditions":"Leukemia","enrollment":1068},{"nctId":"NCT04324411","phase":"PHASE2, PHASE3","title":"Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-04-01","conditions":"Autoimmune Anemia","enrollment":50},{"nctId":"NCT01183884","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Neuroblastoma","enrollment":46},{"nctId":"NCT00617409","phase":"PHASE2","title":"To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-10-02","conditions":"Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT01987297","phase":"PHASE4","title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Acute Promyelocytic Leukemia","enrollment":738},{"nctId":"NCT01183897","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08-12","conditions":"Neuroblastoma","enrollment":31},{"nctId":"NCT01183429","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08-12","conditions":"Neuroblastoma","enrollment":39},{"nctId":"NCT00413166","phase":"PHASE2","title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Acute Promyelocytic Leukemia","enrollment":78},{"nctId":"NCT03259516","phase":"PHASE1, PHASE2","title":"Nivolumab With Chemotherapy in Refractory MDS","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2017-05-25","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT02717884","phase":"PHASE1, PHASE2","title":"Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)","status":"UNKNOWN","sponsor":"Michael Luebbert","startDate":"2015-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":60},{"nctId":"NCT01237808","phase":"PHASE3","title":"Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2011-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":144},{"nctId":"NCT00334789","phase":"PHASE1","title":"Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-12","conditions":"Adult Solid Neoplasm","enrollment":51},{"nctId":"NCT00200161","phase":"PHASE2","title":"Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-08-09","conditions":"Glioblastoma, Gliomas","enrollment":127},{"nctId":"NCT00852709","phase":"PHASE1","title":"Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-09-01","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders","enrollment":35},{"nctId":"NCT02758990","phase":"NA","title":"Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application","status":"TERMINATED","sponsor":"Verifomics LLC","startDate":"2016-03","conditions":"Obesity, Rhinitis, Rhinitis, Allergic","enrollment":16},{"nctId":"NCT00006239","phase":"PHASE1","title":"Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-12","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases","enrollment":""},{"nctId":"NCT00151242","phase":"PHASE2, PHASE3","title":"Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2004-07","conditions":"Acute Myeloid Leukemia","enrollment":920},{"nctId":"NCT01667263","phase":"PHASE2","title":"The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2012-06-01","conditions":"Autoimmune Thrombocytopenia","enrollment":130},{"nctId":"NCT00808899","phase":"PHASE2","title":"Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-12","conditions":"Neuroblastoma","enrollment":4},{"nctId":"NCT02548052","phase":"PHASE1","title":"Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-22","conditions":"Psoriasis","enrollment":15},{"nctId":"NCT00151255","phase":"PHASE3","title":"All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2004-06","conditions":"Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT01275274","phase":"PHASE2","title":"Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-01","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":41,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":31,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME"},{"count":26,"reaction":"NEUTROPENIA"},{"count":25,"reaction":"IDIOPATHIC INTRACRANIAL HYPERTENSION"},{"count":24,"reaction":"DIFFERENTIATION SYNDROME"},{"count":20,"reaction":"LEUKAEMIA RECURRENT"},{"count":19,"reaction":"PYREXIA"},{"count":18,"reaction":"INTENTIONAL PRODUCT USE ISSUE"},{"count":18,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":18,"reaction":"WHITE BLOOD CELL COUNT INCREASED"}],"_approvalHistory":[],"publicationCount":10396,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vesanoid"],"phase":"phase_3","status":"active","brandName":"All trans-retinoic acid","genericName":"All trans-retinoic acid","companyName":"Mahmoud Ramadan mohamed Elkazzaz","companyId":"mahmoud-ramadan-mohamed-elkazzaz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"All-trans-retinoic acid (ATRA) binds to retinoic acid receptors to promote differentiation of acute promyelocytic leukemia cells and induce apoptosis of leukemic blasts. Used for Acute promyelocytic leukemia (APL), particularly t(15;17) positive disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}